Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy

George S. Laszlo, Brenda M. Sandmaier, David J. King, Allie R. Kehret, Kyle E. Nyberg, Jacob W. Barton, Frances M. Cole, Junyang Li, Margaret C. Lunn-Halbert, Donald K. Hamlin, D. Scott Wilbur, Johnnie J. Orozco, Shannon L. Dexter, Roland B. Walter

Blood (2024) 144 (Supplement 1): 4779.

https://doi.org/10.1182/blood-2024-201016

Published: 2024

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML

Gail J. Roboz, Laura E. Finn, Johnnie J. Orozco, Mohamed Hegazi, Avinash Desai, Mary Chen, Gary J. Schiller

Blood (2023) 142 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2023-178802

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

Melissa L Comstock, Shyril O'Steen, Yukang Lin, Donald Hamlin, D Scott Wilbur, Johnnie J. Orozco, Rainer F. Storb, Roland B. Walter, Pinar Ataca Atilla, Brian G Till, Geoffrey R Hill, Brenda M. Sandmaier, Damian J Green

Blood (2023) 142 (Supplement 1): 53.

https://doi.org/10.1182/blood-2023-188055

Published: 2023

Journal Articles

Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison

Lucas Zarling, Philip Stevenson, Lorinda A. Soma, Christen H. Martino, Mary-Elizabeth M. Percival, Anna B. Halpern, Cristina Ghiuzeli, Pamela S. Becker, Vivian G. Oehler, Jason P. Cooper, Johnnie J. Orozco, Paul C. Hendrie, Roland B. Walter, Elihu H. Estey, Ryan D. Cassaday

Blood (2022) 140 (Supplement 1): 6046–6048.

https://doi.org/10.1182/blood-2022-170016

Published: 2022

Journal Articles

Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study

Anna B. Halpern, Eduardo P Rodríguez-Arbolí, Megan Othus, Kelsey-Leigh A Garcia, Mary-Elizabeth M. Percival, Ryan D. Cassaday, Vivian G. Oehler, Pamela S. Becker, Jacob S. Appelbaum, Janis L. Abkowitz, Johnnie J. Orozco, Sioban B. Keel, Paul C. Hendrie, Bart L. Scott, Cristina Ghiuzeli, Roland B. Walter, Elihu H. Estey

Blood (2022) 140 (Supplement 1): 8999–9001.

https://doi.org/10.1182/blood-2022-159882

Published: 2022

Journal Articles

Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML

Gary J. Schiller, Laura Finn, Mohamed M. Hegazi, Johnnie J. Orozco, Avinash Desai, Mary M Chen, Gail J. Roboz

Blood (2022) 140 (Supplement 1): 3336–3337.

https://doi.org/10.1182/blood-2022-157588

Published: 2022

Journal Articles

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, Megan Othus, Mary-Elizabeth M. Percival, Paul C. Hendrie, Bart L. Scott, Jacob S. Appelbaum, Anna B. Halpern, Vivian G. Oehler, Johnnie J. Orozco, Sioban B. Keel, Janis L. Abkowitz, Jason P. Cooper, Ryan D. Cassaday, Kaysey F. Orlowski, Anise J. Marshall, Clarisa N. Brown, Elihu H. Estey, Roland B. Walter

Blood (2021) 138 (Supplement 1): 34.

https://doi.org/10.1182/blood-2021-151658

Published: 2021

Journal Articles

Reduced-Intensity Therapy with Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Yields Durable Remissions in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Final Results of a Phase II Trial

Ryan D. Cassaday, Kelsey-Leigh A. Garcia, Olga Sala-Torra, Philip A. Stevenson, Christen H. Martino, Yajuan J. Liu, Min Fang, Mary-Elizabeth M. Percival, Anna B. Halpern, Pamela S. Becker, Vivian G. Oehler, Andrei R Shustov, Jason P. Cooper, Johnnie J. Orozco, Paul C. Hendrie, Roland B. Walter, Jerry P. Radich, Lorinda A. Soma, Elihu H. Estey

Blood (2021) 138 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2021-145648

Published: 2021

Journal Articles

Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML

Gary J. Schiller, Laura Finn, Gail J. Roboz, Johnnie J. Orozco, Tiffany Lin, Mary M Chen, Mohamed M. Hegazi

Blood (2021) 138 (Supplement 1): 3412.

https://doi.org/10.1182/blood-2021-146018

Published: 2021

Journal Articles

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Blood (2021) 138 (Supplement 1): 1791.

https://doi.org/10.1182/blood-2021-148497

Published: 2021

Journal Articles

Development of Astatine-211 ( 211 At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies

George S. Laszlo, Johnnie J. Orozco, Allie R. Kehret, Margaret C. Lunn, Donald K. Hamlin, D. Scott Wilbur, Shannon L. Dexter, Melissa C. Comstock, Shyril O'Steen, Damian J. Green, Roland B. Walter

Blood (2021) 138 (Supplement 1): 3341.

https://doi.org/10.1182/blood-2021-152105

Published: 2021

Journal Articles

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

Shyril O’Steen, Melissa L. Comstock, Johnnie J. Orozco, Donald K. Hamlin, D. Scott Wilbur, Jon C. Jones, Aimee Kenoyer, Margaret E. Nartea, Yukang Lin, Brian W. Miller, Theodore A. Gooley, Sherilyn A. Tuazon, Brian G. Till, Ajay K. Gopal, Brenda M. Sandmaier, Oliver W. Press, Damian J. Green

Blood (2019) 134 (15): 1247–1256.

https://doi.org/10.1182/blood.2019001250

Published: 2019

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Phuong T. Vo, MD, Ted Gooley, PhD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Robyn Haaf, BS, Margaret E. Nartea, BS, Rainer F. Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD PhD, John M. Pagel, MD PhD, Brenda M. Sandmaier, MD

Blood (2018) 132 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2018-99-111915

Published: 2018

Journal Articles

The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models

Shyril O'Steen, PhD, Melissa C. Comstock, BS, Johnnie J. Orozco, MD PhD, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Jon Jones, BS, Aimee Kenoyer, BS, Margaret E. Nartea, BS, Yukang Lin, PhD, Brian W. Miller, PhD, Sherilyn A. Tuazon, MD, Brian G. Till, MD, Ajay K. Gopal, MD, Brenda M. Sandmaier, MD, Oliver W. Press, MD PhD, Damian J. Green, MD

Blood (2018) 132 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2018-99-119555

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Ehab L. Atallah, MD, Johnnie J. Orozco, MD PhD, Michael Craig, MD, Moshe Yair Levy, MD, Laura E. Finn, MD, Sharif S. Khan, MD, Alexander E. Perl, MD, Jae H. Park, MD, Gail J. Roboz, MD, William Tse, MD, Kebede H. Begna, MD, Raya Mawad, MD, David A. Rizzieri, MD, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2018) 132 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2018-99-111951

Published: 2018

Journal Articles

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

Damian J. Green, Shyril O’Steen, Yukang Lin, Melissa L. Comstock, Aimee L. Kenoyer, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Margaret Nartea, Mark D. Hylarides, Ajay K. Gopal, Theodore A. Gooley, Johnnie J. Orozco, Brian G. Till, Kelly D. Orcutt, K. Dane Wittrup, Oliver W. Press

Blood (2018) 131 (6): 611–620.

https://doi.org/10.1182/blood-2017-09-807610

Published: 2018

Includes: Supplemental data

Journal Articles

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Sherilyn A Tuazon, MD, Brenda M. Sandmaier, MD, Johnnie J. Orozco, MD PhD, Ajay K. Gopal, MD, Leona A. Holmberg, MD PhD, Pamela S. Becker, MD PhD, Sally J. Lundberg, Brian G. Till, MD, Margaret E. Nartea, Ted Gooley, PhD, Darrell R. Fisher, PhD, Joseph G. Rajendran, MD, Oliver W. Press, MD PhD, William I. Bensinger, MD, Damian J. Green, MD

Blood (2017) 130 (Supplement 1): 910.

https://doi.org/10.1182/blood.V130.Suppl_1.910.910

Published: 2017

NARROW

Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model

Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison

Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study

Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Reduced-Intensity Therapy with Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Yields Durable Remissions in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Final Results of a Phase II Trial

Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Development of Astatine-211 ( 211 At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only